Robert Alpern J.'s Insider Trades & SAST Disclosures
Robert Alpern J.'s most recent trade in Abbvie Inc was a trade of 1,203 Common Stock, $0.01 par value done . Disclosure was reported to the exchange on May 9, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert Alpern J..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,203 | 35,646 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2025 | 1,635 | 40,798 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 59 | 10,093 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 35 | 9,907 | - | - | Stock Equivalent Units | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 69 | 9,988 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 42 | 9,788 | - | - | Stock Equivalent Units | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 69 | 9,872 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 37 | 9,655 | - | - | Stock Equivalent Units | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2024 | 75 | 9,754 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2024 | 43 | 9,541 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2024 | 1,322 | 34,443 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2024 | 1,866 | 39,163 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2024 | 69 | 9,628 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2024 | 41 | 9,408 | - | - | Stock Equivalent Units | |
| Abbott Laboratories | Robert Alpern J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2023 | 71 | 9,512 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert Alpern J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2023 | 48 | 9,285 | - | - | Stock Equivalent Units | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2023 | 81 | 9,392 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2023 | 50 | 9,139 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | 07 Sep 2023 | 129 | 33,121 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 72 | 9,266 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 55 | 9,001 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 1,450 | 32,992 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 1,816 | 37,297 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 77 | 9,151 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 47 | 8,856 | - | - | Stock Equivalent Units | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 71 | 9,030 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 46 | 8,723 | - | - | Stock Equivalent Units | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 81 | 8,918 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 55 | 8,598 | - | - | Stock Equivalent Units | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 72 | 8,800 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 47 | 8,458 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 1,421 | 31,542 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2022 | 1,602 | 35,481 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 66 | 8,690 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 44 | 8,335 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 66 | 8,068 | - | - | Stock Equivalent Units | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 66 | 8,505 | - | - | Stock Equivalent Units | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 67 | 8,408 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 63 | 7,914 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 115.96 per share. | 07 May 2021 | 1,681 | 30,121 (0%) | 0% | 116.0 | 194,929 | Common Stock, $0.01 par value |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Apr 2021 | 1,499 | 33,879 (0%) | 0% | 0 | Common shares without par value | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 66 | 7,764 | - | - | Stock Equivalent Units | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 65 | 8,308 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 82 | 7,489 | - | - | Stock Equivalent Units | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 72 | 8,116 | - | - | Stock Equivalent Units | |
| Abbott Laboratories | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 86 | 8,015 | - | - | Stock Equivalent Units | |
| Abbvie Inc | Robert J. Alpern | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 71 | 7,353 | - | - | Stock Equivalent Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges